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Abstract 
Introduction: Oral contraceptives (OCs) are considered as one of the most common risk factor of venous throm-
boembolism (VTE) in childbearing age. Some of the recent researches indicate that the odds of VTE may be even 
higher with newer generations of OCs. The present meta-analysis was designed to evaluate the effect of different 
generation of OCs on the occurrence of VTE. Methods: Two researchers independently ran a thorough search in 
Pubmed, ISI Web of Science, EMBASE, CINAHL and Scopus databases regarding study keywords including throm-
boembolic event, thromboembolism, embolism, thromboembolic, thrombotic and thrombosis, combined with oral 
contraceptive. The outcomes were the incidence of diagnosed thromboembolism, such as deep vein thrombosis, 
pulmonary embolism and cerebral venous thrombosis. Based on the heterogeneity of the studies, random effect 
model was used and pooled odds ratio was reported. Results: Three cohort and 17 case-control studies with 
13,265,228 subjects were entered into meta-analysis. Analysis showed that the odds of VTE in women taking OCs 
are more than three-fold (OR=3.13; 95% CI: 2.61-3.65). The risk of VTE in women taking first-, second- and third-
generation OCs are 3.5 fold (OR=3.48; 95% CI: 2.01-4.94), 3 fold (OR=3.08; 95% CI: 2.43-3.74) and 4.3 fold 
(OR=4.35; CI: 3.69‒5.01), respectively. Conclusion: It seems that the risk of VTE is not same between different 
generations of OCs, so that third-generation has highest risk. Taking second and third-generation OCs increases 
the risk of VTE up to 3 and 4.3 fold, respectively. The researchers of the present study suggest that more trials be 
designed in relation to the effect of newer generations of OCs in different communities. 
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Introduction:1 
hromboembolic events are multifactorial phe-
nomena, involving both genetic and acquired 
factors (1). Some of the genetic factors include 
defects in and mutations of the genes of prothrombin 
and factor V Leiden (2-4), whereas acquired factors in-
clude pregnancy, the postpartum period, obesity, lack of 
activity, and aging (5-8). At present, oral contraceptives 
(OCs) are considered one of the most common risk fac-
tors of venous thromboembolism (VTE) in women at 
childbearing age. OCs are among the most commonly 
used methods to prevent pregnancy. The official reports 
of 2012 show that OCs have been used by 11 million 
women (17%) in the United States and 100 million 
women worldwide (9, 10). These pills may have life-
threatening side effects, including myocardial infarc-
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tion, strokes, and VTE (11), and the odds of such inci-
dents in women taking OCs are three times higher than 
those in nonusers (12-14). In recent decades, the chem-
ical composition of OCs has undergone changes. Com-
pounds containing estrogen are known as important 
risk factors for this medical condition in postmenopau-
sal women (15, 16). In this context, the estrogen con-
tent of OCs was decreased and new progestins were 
incorporated. Despite these changes, the incidence of 
vascular complications resulting from the use of these 
pills is still high (17, 18). A meta-analysis of observa-
tional studies and clinical trials on postmenopausal 
women showed that the use of OCs containing estrogen 
increased the risk of VTE by up to three fold, which sig-
nificantly increased in the first year of the drug use and 
when combined with other risk factors (15). Further-
more, the newer generation OCs presented higher odds 
of a VTE risk, when compared with the older generation 
OCs (2, 12, 19). Therefore, the present meta-analysis 
was designed to evaluate the effects of different genera-
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Figure 1: the flowchart of the study.  
 
Methods: 
This study was designed based on the instructions for 
conducting Meta-analysis of Observational Studies in 
Epidemiology Statement (20).  
Search Strategy 
Two independent reviewers conducted an extensive 
search in various databases. All the articles indexed in 
the electronic databases of PubMed, ISI Web of Scienc-
es, EMBASE, CINAHL, and Scopus from 2000 to 2012 
were evaluated. The keywords were determined by us-
ing the Medical Subject Headings (MeSH) of PubMed, 
which consisted of words related to “thrombosis,” in-
cluding thromboembolic event, thromboembolism, em-
bolism, thromboembolic, thrombotic, and thrombosis, 
combined with oral contraceptive. Only articles in Eng-
lish were evaluated. To evaluate additional articles with 
unpublished data, hand search was carried out in the 
list of “relevant studies.”  
Selection Criteria  
The cohort and case-control studies conducted on 15–
50-year-old female subjects, who took oral contracep-
tives, were included. The inclusion criteria were as fol-
lows: 1) study population consisting of subjects taking 
oral contraceptives; 2) studies in which the clinical out-
comes, including deep vein thrombosis (DVT), pulmo-
nary embolism (PE), and cerebral venous thrombosis 
(CVT) had been evaluated; 3) studies in which diagnosis 
of thromboembolism had been carried out by using 
standard and well-validated diagnostic criteria; and 4) 
studies with a nonuser control group. Studies that were 
conducted before 2000, related to special populations 
such as postpartum, and of editorial, review, and letter 
to the editor types were excluded.  
Quality assessment and data extraction 
The summaries of the studies were independently eval-
uated and recorded in data sheets by the two reviewers. 
The data were collected in a blind manner in relation to 
the authors, journal, and organization or institution. 
The reason for exclusion was recorded and disagree-
ment was resolved by a third reviewer. The number of 
subjects, adjusted odds ratio (OR), relative risk (rr), and 
rate ratio with 95% confidence interval (CI) were ex-
tracted from the relevant studies. If it was not possible 
to extract data from a study, the corresponding author 
was asked to provide the necessary data. The data and 
results in relation to the generation of OCs were rec-
orded separately. Finally, the findings were incorpo-
rated into a flowchart designed based on Preferred Re-
porting Items for Systematic Reviews and Meta-
Analyses (PRISMA) Statement Guidelines (21). 
Data Synthesis 
The outcomes consisted of DVT, PE, and CVT. Three co-
hort (22-24) and 17 case-control studies (2-4, 14, 19, 
25-36) met the inclusion criteria. One study had calcu-
lated the rate ratios (23), one had determined the rr 
(24) and the others had evaluated the OR (2-4, 14, 19, 
22, 25-36).  
As the type of the study had no effect on the results, 
based on a logistic regression model, all the 20 articles 
were included into one meta-analysis. In the sensitivity 
analysis, only studies with quality rates of good and fair 
were included. The funnel plot was used to evaluate 
selection bias (37) and “trim and fill” technique was 
used to identify publication bias (38, 39). The Methods 
Guide for Effectiveness and Comparative Effectiveness 
Reviews of the Agency for Healthcare Research and 
 2378 Article excluded 
- Not relevant (n= 2170) 
- Editorials/commentaries (n= 51) 




 10 Full-text articles excluded 
- Duplicate reports (n=4) 
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Quality was used to evaluate the quality of the studies 
(40). The reviewers evaluated each study in relation to 
its design, presence of bias in the selection of samples, 
and performance and reporting of outcomes. Each 
study was given a general score of good, fair, or poor. 
Studies with the least bias were given a score of “good;” 
studies in which there was a possibility of bias, but their 
results had not been influenced, were given a score of 
“fair;” and studies with obvious indications of bias and 
elimination of large amounts of data or great discrepan-
cies in reporting the outcomes were given a general 
score of “poor.” The inter-rater reliability of the two 
reviewers was 83%.  
Chi-squared and I2 tests were used to evaluate the het-
erogeneity among the studies, and statistical signifi-
cance was defined at p < 0.1. If the studies were homo-
geneous, then the fixed effect model was used; other-
wise, meta-analysis was conducted based on the ran-
dom effect model. The results of the studies were 
pooled and an overall OR was calculated, which indicat-
ed the odds of affliction with thromboembolism in 
women taking OCs, when compared with that in nonus-
ers. The calculated OR was also presented separately in 
relation to the generation of OCs. As meta-analyses 
were performed in at least three studies in which OR 
had been presented, it was not possible to report the OR 
for the fourth-generation OCs. Statistical analyses were 
carried out by STATA 11.0 (Stata Corporation, College 
Station, TX).  
Results: 
After elimination of duplicate reports, 162 potentially 
relevant articles were identified (Figure 1).  A total of 
20 articles (13,265,228 subjects) were included in the 
meta-analysis, consisting of three cohort (22-24) and 
17 case-control studies (2-4, 14, 19, 25-36) (Table 1 and 
Figure 1). Five studies had evaluated the relationship 
between first-generation OCs and VTE (4, 14, 24, 30, 
32); eight studies had examined the second-generation 
OCs (4, 14, 19, 23, 24, 29-32) and seven studies had in-
vestigated the third-generation OCs (14, 19, 23, 24, 29, 
30, 32). The endpoint of all these studies was the occur-
rence of DVT, pulmonary embolism, and cerebral embo-
lism. The diagnostic tests used were Doppler ultra-
sound for DVT and computed tomography angiography 
for pulmonary and cerebral embolism. Logistic regres-
sion analysis showed the feasibility of pooling the stud-
ies (p = 0.12).  
Heterogeneity and publication bias  
The studies included in the meta-analysis were not suf-
ficiently homogeneous to allow conducting meta-
analysis based on the fixed effect model. Therefore, in 
all the analyses, random effect model was used. There 
were no selection and publication biases in three of the 
four meta-analyses (one meta-analysis of the first-
generation OCs had publication bias). The limited num-
ber of studies (five studies) did not allow the exclusion 
of outlier studies to eliminate bias. The results of these 
four meta-analyses were as follows. 
Meta-analysis  
A) Effect of OCs on incidence of VTE (without generation 
consideration) 
Systematic review of 19 studies showed an OR/rr range 
of 1.32–8.45, which was statistically significant (2-4, 14, 
19, 22-36). Only one study did not indicate an increase 
in the OR (3). The meta-analysis showed that the odds 
of VTE in women taking OCs was threefold higher than 
that in nonusers (OR = 3.13; 95% CI: 2.61–3.65) (Figure 
2).  
B) Effect of first-generation OCs on incidence of VTE 
All the five studies on the relationship between the in-
cidence of VTE and first-generation OCs showed a high 
OR (26,327 users and 5,909,630 nonusers). Of these 
five studies, four were case-control (4, 14, 30, 32) and 
one was cohort (24). This increased risk was significant 
in four studies (4, 14, 30, 32). The adjusted OR range in 
the studies was 1.57–8.1. The meta-analysis showed 
that the odds of VTE in women taking first-generation 
OCs was 3.5-fold higher than that in nonusers (OR = 
3.48; 95% CI: 2.01–4.94) (Figure 3).  
C) Effect of second-generation OCs on incidence of VTE  
The eight relevant studies indicated a significant rela-
tionship between the second-generation OCs and VTE 
(4, 14, 19, 23, 24, 29, 30, 32). Among these studies 
(2,537,189 users and 10,703,873 nonusers), six were 
case-control (4, 14, 19, 29, 30, 32) and two were cohort 
(23, 24). Separate subgroup analysis of the study type 
showed that the overall OR reported in the case-control 
studies was 3.57 (95% CI: 2.92–4.2) and the rr reported 
in the two cohort studies was 2.09 (95% CI: 1.82–2.34). 
The overall OR for the incidence of VTE in the second-
generation OC users was 3.08 (95% CI: 2.43–3.74) 
(Figure 4). 
D) Effect of third-generation OCs on incidence of VTE 
Seven studies (2,536,993 users and 10,703,127 nonus-
ers) had evaluated the effects of third-generation OCs 
on the incidence of VTE (14, 19, 23, 24, 29, 30, 32). 
Among these, five were case-control (4, 14, 19, 29, 30, 
32) and two were cohort (23, 24). Subgroup analysis 
based on the type of the study showed an OR range of 
3.39–7.7 (overall OR = 4.74; CI: 3.42–6.08). The rr calcu-
lated from the two cohort studies were 4.0 and 4.47, 
respectively. The pooled analysis of all the seven stud-
ies showed an OR of 4.35 (CI: 3.69–5.01) (Figure 5). 
Discussion: 
The results of this meta-analysis showed that OCs are 
important risk factors for VTE in women. The risk of 
such events was higher with the use of third-generation 
OCs, as evidenced by other meta-analyses (41-43).  
A study performed in 2001 showed that the risk of VTE 
in women taking third-generation OCs was 1.7-fold 
higher than that in women taking second-generation  
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Table 1: Studies of oral contraceptive use, thrombosis and Thromboembolism event  
Authors, year and 
location of study 
No. of cas-
es/controls Results Adjustments Weaknesses Quality 
Case-Control studies 
Austin et al.,  
2009 (25) 
USA 
46 cases and 
170 controls 
The risk of VTE: 
OR=2.6 
Age and household income Analysis was not adjusted for other 
Potential confounders 
Small sample size. 
The participation rate of cases and 
controls was low 
Selection bias: The use of clinic 
controls may result in an overesti-
mate of OCs. 
Fair 
Aznar et al.,  
2000 (26) 
Spain 
84 cases and 89 
controls 
The risk of VTE: 
Healthy users: OR= 3.5 
Suspected thrombophilia: OR= 14.3 
DVT patients: OR=6.9 
None Unadjusted analysis for potential 
confounders. 
The participation rate of cases and 
controls was low. 
Fair 
Barsoum et al.,  
2010 (34) 
USA 
125 cases and 
143 controls 
The risk of VTE:                                            
Total: OR=3.0 
Estrogen alone: OR=1.81 
Progestin alone: OR=2.53 (NS) 
Non- estrogen OCs plus progestin: OR=2.53 
Age, BMI and all previously 
identified VTE risk factors 
The participation rate of cases and 
controls was low.  
Findings may not be generalizable 
to other races or ethnicities. 
Sample size was too small to test 
the effect of different estrogen and 
progestin combinations, doses.  
Good 
Bergendal et al., 
2012 (33) 
Sweden 
766 cases and 
674 controls 
Use of CHC was associated with an eight-fold 
increased risk of VTE: OR=8.45 
No risk increase associated with use of POC: 
OR=0.98  
Use of MHT increased risk for VTE: OR=3.73 
Age, BMI, smoking, use of 
hormones, bed rest/minor 
trauma, surgery, cast, sur-
gery and cast, the pro-
thrombin mutation and/or 
factor V Leiden 
The participation rate of cases and 
controls was low. 
Retrospective design. 
Higher non-participant rate among 
the controls. 
Possible recall-bias. 
No specified diagnostic criteria for 
assessment of menopausal status. 
Fair 
Bloemenkamp et al., 
2000 (27) 
Netherlands 
155 cases and 
169 controls 
The risk of DVT in healthy user: 
First six month of use: OR=3.0 
First years of use: OR=2.0 
The risk of development of DVT in combined 
with thrombophilia: 
First six month of use: OR=18.5 
First years of use: OR=11.0 
Age, family history of ve-
nous thrombosis, history of 
pregnancy  
The most important genetic risk 
factors for venous thrombosis were 
not discovered.  
Large confidence intervals. 
The participation rate of cases and 
controls was low. 
Good 
VTE: Venous thromboembolism; DVT: Deep vein thrombosis; VT: Venous thrombosis; CHC: Combined hormonal contraceptives; POC: Progestogen-only contraception; MHT: 
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Table 1: Studies of oral contraceptive use, thrombosis and Thromboembolism event (continue)  
Authors, year and 
location of study 
No. of cas-
es/controls Results Adjustments Weaknesses 
Quali-
ty 
Dinger et al.,  
2010 (28) 
Germany 
680 cases and 
2,720 controls 
The risk of VTE associated with current COC 
use: OR=2.3 
DNG/EE vs. any other low-dose COCs: OR=0.9 
DNG/EE vs. low-dose LNG/EE: OR=1.1 
DRSP/EE vs. low-dose LNG/EE: OR=1.0 
Personal history of VTE, fami-
ly history of VTE, body mass 
index, duration of combined 
oral contraceptive use, parity, 
educational level, chronic 
disease, concomitant medica-
tion and smoking 
Recruit only survivors of VTE. 
Possible recall bias. 
Good 
Heinemann et al., 
2002 (30) 
Germany 
605 cases and 
2,941 controls 
The risk of VTE:  
For all cases: OR=3.4 
For hospital cases: OR=3.7 
The risk of Idiopathic VTE:  
For all cases: OR=5.4 
For hospital cases:OR=9.1 
Age, BMI, parity, ever-use of 
OCs 
Did not assess of other potential con-
founder. 
Good 
Heinemann et al., 
2010 (29) 
Austria 
362 cases and 
1,505 controls 
The risk of VTE:  
OCs containing gestodene: OR=3.39 
OCs containing progestin: OR=3.14 
Age, BMI, parity and ever-use 
of hormonal contraceptives 
Limit the generalizability of results to 
other regions and/or other racial and 
ethnic groups. 
Mild or atypical VTE cases were under-
reported in this study. 
Good 
Legnani et al.,  
2002 (2) 
Italy 
301 cases and 
650 controls 
The risk of DVT: 
In the absence of both mutations was : OR=2·4 
In the presence of R506Q mutation: OR=41·0,  
In the presence of G20210A mutation: 
OR=58·6 
Both mutations: OR=86·5. 
 
Age and presence of other 
thrombophilic defects 




Lidegaard et al., 
2002 (14) 
Denmark 
654 cases and 
1,921 controls 
The risk of  VTE: 
Second  generation OCs: OR=2.9 
Third  generation OCs: OR=4.0 
Age, year, family history of 
VTE, BMI, years of schooling, 
smoking, diabetes, coagula-
tion disturbances, and previ-
ous delivery 
Analysis was not adjusted for duration 
of use and other potential confounders. 
Fair 
Pomp et al.,  
2008 (31) 
Netherlands 
362 cases and 
357 controls 
The Risk of VTE: 
Current smokers and OCs users: OR= 8.8 
Non-smoker and OCs user: OR=3.9 
Age, sex, BMI, parity and fi-
brinogen levels 
The participation rate of cases and 
controls was low. 
 
Fair 
Santamaria et al., 
2001 (3) 
Spain 
100 cases and 
273 controls 
The Risk of VTE: 
Without defect: OR=1.3 (NS) 
PT20210A mutation+ OCs use: OR=2.9 
Factor V Leiden carriers + OCs: OR=1.2 (NS) 
Age, including the PT20210-A 
and the FVL mutations 
Sample size was too small Self-report 
of OCs use. 
Unadjusted analysis for other potential 
confounders. 
Good 
VTE: Venous thromboembolism; DVT: Deep vein thrombosis; VT: Venous thrombosis; CHC: Combined hormonal contraceptives; POC: Progestogen-only contraception; MHT: 
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Table 1: Studies of oral contraceptive use, thrombosis and Thromboembolism event (continue)  
Authors, year and 
location of study 
No. of cas-
es/controls Results Adjustments Weaknesses Quality 
Santamaria et al., 
2001 (3) 
Spain 
100 cases and 
273 controls 
The Risk of VTE: 
Without defect: OR=1.3 (NS) 
PT20210A mutation+ OCs use: OR=2.9 
Factor V Leiden carriers + OCs: OR=1.2 (NS) 
Age, including the PT20210-
A and the FVL mutations 
Sample size was too small  
Self-report of OCs use. 
Unadjusted analysis for other poten-
tial confounders. 
Good 
Sidney et al., 
 2004 (4) 
USA 
196 cases and 
746 controls 
The Risk of DVT: 
OCs user: OR=4.07 
Factor V Leiden mutation:  OR=7.1 
Prothrombin mutation: OR=2.83 
MTHFR C677T mutation: OR=0.26 
Age, race/ethnicity, income 
and BMI 
Possible recall bias and diagnostic 
bias. 
Unadjusted analysis for potential 
confounders. 
Fair 
Smith et al.,  
2004 (35) 
USA 
493 cases and 
1728 controls 
The Risk of VTE:                                       
Total: OR= 1.75 
Estrogen only: OR: 0.92 (NS) 
CEE: OR: 1.65 
CEE + Progestin:OR: 2.17 
Age, hypertension, calendar 
year, race, and cancer histo-
ry 
Use of hormone therapy was not 
randomly assigned. 
Findings are generalizable only to 
similar populations. 
Good 
Suissa et al.,  
2000 (19) 
Germany and UK 
128 cases and 
650 controls 
The risk of  VTE: 
Second  generation OCs: RR=4.7 
Third  generation OCs: RR=2.9 
Age, country, BMI, alcohol, 
smoking and duration of use 
Defect in randomization. 
Fair 
Van Hylckama  et l., 
2009 (32) 
Netherlands 
1,524 cases and 
1,760 controls 
The risk of DVT: 
Total:OR= 5.0 
OCs containing levonorgestrel: OR=3.6 
OCs containing  gestodene: OR=5.6 
OCs containing  desogestrel: OR=7.3 
OCs containing  Cyproterone acetate: OR=6.8 
OCs containing  drospirenone: OR=6.3 
Age and period of inclusion Unadjusted analysis for potential 
confounders. 
The participation rate of cases and 
controls was low. 
Potential recall bias. 
Good 
Cohort studies 




5,866 OCs Users 
and  
9,326 Non-user 
The risk of VTE in OCs users and hormone 
therapy group was same: RR=1.9 
Sex, age, calendar year, BMI, 
smoking, cancer, fractures 
in the last month, surgery in 
the last 6 months, use of 
warfarin sodium,  
The authors did not calculate the 
incidence of VTE by weighting the 
number of newly diagnosed VTE 
cases identified by the confirmation 
rate obtained in the validation study. 
Good 




Users and  
4,802,168 Non-
user 
The Risk of VTE: 
<1 year: RR=4.17 
1-4 years: RR= 2.98 
>4 years: RR= 2.76 
Current use of oral contra-
ceptives, calendar year, and 
educational level 
Family predisposition and body mass 
index were not adjusted. 
Validity of each included diagnosis of 
VTE was not checked. 
Good 




Users and  
5,892,182 Non-
user  
The risk of VTE compared with users of com-
bined oral contraceptives containing levo-
norgestrel: 
Transdermal patches: RR=2.3  
The vaginal ring: RR=1.9 
Age, calendar year, 
and education 
Analysis could not control for family 
disposition or for BMI. 
Good 
VTE: Venous thromboembolism; DVT: Deep vein thrombosis; VT: Venous thrombosis; CHC: Combined hormonal contraceptives; POC: Progestogen-only contraception; MHT: 
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             Figure 2: Odds ratio of the incidence of venous thromboembolism due to the use of OCP compared to non-users.  
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     Figure 4: Evaluation of the OR of venous thromboembolism in women taking second-generation OCs.  
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A similar result was also reported by Martinez et al., 
who demonstrated that the risk of VTE associated with 
third-generation OCs was greater than that associated 
with second-generation OCs (43).  
A review of the literature and meta-analysis of 19 case-
control and cohort studies showed that, in general, the 
use of OCs increased the odds of VTE by almost three-
fold, when compared with the nonusers (11). These OR 
values are consistent with the results obtained in the 
present study. Although the duration of drug use was 
different, in the present meta-analysis, VTE frequently 
occurred in the first year of use. Previous studies have 
demonstrated that the incidence of VTE was higher in 
women who recently started taking OCs (23, 44-46).  
Quality issue  
In the present study, the application of three techniques 
resulted in qualitative confirmation of meta-analysis. 
Initially, subgroup analysis was carried out separately 
for each generation of OCs. In this context, only con-
firmed and documented cases of thrombosis were in-
cluded in the meta-analysis. In the second stage, to 
evaluate the implementation of appropriate adjust-
ments for confounding factors, OR was separately calcu-
lated for approximate OR or rr and was adjusted. As the 
OR calculated from both the analyses were almost the 
same, the presence of a confounding factor was unlike-
ly. Therefore, only adjusted OR or rr was reported. In 
addition, in the present meta-analysis, only women at 
childbearing age (age under 50 years) were included, 
which eliminated the effect of age. In the third stage, the 
quality assessment of exposure was evaluated, which 
was conducted by separating the different generations 
of OCs. Although the definitions of drug generations 
were not completely similar in the included studies, 
they did not affect the pooled OR, because of the much 
less weight of studies with incongruent definitions (4, 
19, 30, 32) (Figure 2-4). However, the calculated pooled 
OR might have been underestimated; because (i) it was 
not possible to completely eliminate publication bias, 
particularly in the case of OR calculated for the first-
generation OCs; (ii) some pharmaceutical companies 
might refrain from disclosing the results of studies to 
protect personal benefits, resulting in an increase in 
publication bias (47); and (iii) the use of rr calculated 
from the community data (especially from cohort stud-
ies) is generally less frequent, when compared with the 
results obtained from matched regression analyses.  
Furthermore, the differences in the incidence rate of 
VTE with the use of first-, second-, and third- generation 
OCs might be attributed to the differences in the popu-
lations of women taking these drugs, because new users 
have a tendency to use new generations, but old users 
prefer to use the same drug that they had been using. 
Moreover, new users might consist of women who are 
genetically predisposed to VTE or have an acquired 
susceptibility to VTE. In this context, it has been shown 
that older users are resistant to the complications of the 
drug, which might result in erroneously reporting a 
higher risk of VTE in newer generations, when com-
pared with older generations. However, as drug use 
duration had not been adjusted only in one study (14) 
the presence of confounding factors was very improba-
ble.  
Limitation 
One of the most important limitations of the present 
study was the meta-analysis nature of the observational 
studies. The observational studies, with their inherent 
limitation for the evaluation of all the confounding fac-
tors, could not reliably establish the cause-and-effect 
relationships. Another limitation was the heterogeneity 
of the studies, resulting in designing of meta-analyses 
based on random effect model. Although an attempt 
was made to choose studies similar in methodology and 
to control the confounding factors, this aim could not be 
completely achieved even under ideal conditions. 
Therefore, in the present meta-analysis, the definitions, 
controls for confounding factors, and study populations 
in the studies included were different to some extent. 
For example, the methods used to diagnose and confirm 
thromboembolism in the selected studies were not sim-
ilar. Although only the data of confirmed cases were 
included in the meta-analyses, as the diagnosis of 
thromboembolism was hampered by limitations, some 
patients might have been erroneously classified, thus 
influencing the results.  
Advantages 
In the present study, the databases were extensive 
searched and attempts were made to contact the corre-
sponding authors for acquisition of data. More im-
portantly, apart from evaluation of the effects of all the 
OCs, the results were reported separately for all the 
three generations of OCs. This analysis significantly 
contributed to decreasing bias, and among the four 
analyses, only one had selection and publication biases. 
Another advantage of the present study was the elimi-
nation of data of switchers (women who changed the 
drug that they used owing to pooled side effects) be-
cause changing of the drug has been reported to in-
crease the risk of VTE (19).  
Conclusion: 
It seems that the risk of VTE was not the same between 
different generations of OCs, with third-generation OCs 
presenting the highest risk. The use of second- and 
third-generation OCs increased the risk of VTE by up to 
threefold and 4.3-fold, respectively. Nevertheless, fur-
ther clinical trials in relation to the effect of newer gen-
erations of OCs on different communities are necessary. 
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